Skip to main content

Table 5 EGFR mutation testing between index date and subsequent therapy

From: EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Types of BiomarkersPatients with subsequent therapyPatients who received 1 L EGFR-TKI and had subsequent therapyPatients who received 2 L+ EGFR-TKI and had subsequent therapy
(N = 294),
n (%)
(N = 160),
n (%)
(N = 134),
n (%)
Tested88 (29.9)63 (39.4)25 (18.7)
 Positivea47 (53.4)39 (61.9)8 (32.0)
  T790M mutation25 (53.2)23 (59.0)2 (25.0)
  Exon 19 deletion21 (44.7)16 (41.0)5 (62.5)
  L858R point mutation in exon 2111 (23.4)9 (23.1)2 (25.0)
  Other mutation type2 (4.3)1 (2.6)1 (12.5)
  Unknown0 (0.0)0 (0.0)0 (0.0)
 Negative38 (43.2)22 (34.9)16 (64.0)
 Results pending2 (2.3)1 (1.6)1 (4.0)
 Unsuccessful / indeterminate test1 (1.1)1 (1.6)0 (0.0)
Sample
 Tissue48 (54.5)36 (57.1)12 (48.0)
 Blood35 (39.8)24 (38.1)11 (44.0)
 Unknown3 (3.4)2 (3.2)1 (4.0)
 Urine2 (2.3)1 (1.6)1 (4.0)
  1. 1 L first line, 2 L+ second or later line, EGFR epidermal growth factor receptor, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor
  2. a EGFR mutations are reported among those patients with a positive EGFR test result. Patients may have more than one EGFR mutation